Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 1/20 | 0.70 |
| ▸ | ADRA1D | P25100 | 5/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 5/20 | 0.46 |
| ▸ | ADRA1B | P35368 | 5/20 | 0.46 |
| ▸ | HTR1A | P08908 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | BACE1 | P56817 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4706401 | 0.92 | PDE4B (0.68) | PDE4BADRA1DADRA1AADRA1BHTR1A | |
| SCHEMBL4708054 | 0.92 | PDE4B (0.69) | PDE4BADRA1DADRA1AADRA1BHTR1A | |
| SCHEMBL4708012 | 0.92 | PDE4B (0.67) | PDE4BADRA1DADRA1AADRA1BHTR1A | |
| SCHEMBL4707426 | 0.90 | PDE4B (0.60) | PDE4BADRA1DADRA1AADRA1BHTR1A | |
| SCHEMBL4705728 | 0.87 | PDE4B (0.77) | PDE4BADRA1DADRA1AADRA1BHTR1A | |
| SCHEMBL4706512 | 0.86 | PDE4B (0.67) | PDE4BADRA1DADRA1AADRA1BHTR1A | |
| SCHEMBL4705575 | 0.86 | PDE4B (0.70) | PDE4BADRA1DADRA1AADRA1BHTR1A | |
| SCHEMBL4706133 | 0.85 | PDE4B (0.85) | PDE4BADRA1DADRA1AADRA1BHTR1A | |
| SCHEMBL4706461 | 0.85 | PDE4B (0.74) | PDE4BADRA1DADRA1AADRA1BHTR1A | |
| SCHEMBL4708015 | 0.85 | PDE4B (0.65) | PDE4BADRA1DADRA1AADRA1BHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7459453-B2 | Pyridazin-3(2H)-one derivatives as PDE4 inhibitors | LABORATORIOS ALMIRALL, S.A. (ES) | 2008-12-02 | — | — | US | claimed |
| US-20060052379-A1 | Pyridazin-3(2h)-one derivatives as pde4 inhibitors | LABORATORIOS ALMIRALL, S.A. (ES) | 2006-03-09 | — | — | US | claimed |
| US-7459453-B2 | Pyridazin-3(2H)-one derivatives as PDE4 inhibitors | LABORATORIOS ALMIRALL, S.A. (ES) | 2008-12-02 | — | — | US | disclosed |
| US-20060052379-A1 | Pyridazin-3(2h)-one derivatives as pde4 inhibitors | LABORATORIOS ALMIRALL, S.A. (ES) | 2006-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052379-A1 | Pyridazin-3(2h)-one derivatives as pde4 inhibitors | PDE4A, PDE3A, PDE4B | PDE4B 3/4885ADRA1D 65/4885ADRA1A 113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.